Table 3 Factors associated with tumor stage ≥ pT3 in entire cohort and each risk group

OR

95%CI

p-value

OR

95%CI

p-value

PSAD >0.345 vs ≤0.345 ng/ml/cc

5.850

2.820–12.20

<0.001

4.370

2.000–9.540

<0.001

% positive cores >21.4 vs ≤21.4%

3.150

1.770–5.630

<0.001

2.100

1.110–3.990

0.028

% dominant side >37.5 vs ≤37.5%

2.210

1.250–3.910

0.006

% cancer extent >55.6 vs ≤55.6%

2.600

1.450–4.650

0.001

1.960

1.030–3.720

0.041

NCCN risk high vs intermediate

2.440

1.380–4.320

0.002

1.910

1.020–3.580

0.042

OR

95%CI

p-value

OR

95%CI

p-value

PSAD >0.190 vs ≤0.190 ng/ml/cc

1.920

0.864–4.260

0.110

% positive cores >21.4 vs ≤21.4%

3.260

1.450–7.320

0.004

3.260

1.450–7.320

0.004

% dominant side >36.4 vs ≤36.4%

2.400

1.070–5.380

0.033

% cancer extent >57.1 vs ≤57.1%

2.180

0.970-4.900

0.059

OR

95%CI

p-value

OR

95%CI

p-value

PSAD >0.345 vs ≤0.345 ng/ml/cc

4.730

1.680–13.30

0.003

4.510

1.580–12.90

0.004

% positive cores >35.0 vs ≤35.0%

3.140

1.180–8.390

0.023

% dominant side >40.0 vs ≤40.0%

1.880

0.811–4.360

0.141

% cancer extent >55.6 vs ≤55.6%

2.810

1.170–6.760

0.021